How Moderna's mRNA Vaccine Technology Targets Betacoronaviruses

A patent describing a specific mRNA vaccine design that uses lipid nanoparticles to deliver genetic instructions for building parts of a betacoronavirus to trigger an immune response.

What it covers

The patent claims a vaccine composition that uses messenger RNA (mRNA) to teach the body how to produce a betacoronavirus spike (S) protein. This mRNA is protected and transported into cells using a lipid nanoparticle, which is a tiny fat-based bubble. The specific design includes chemical modifications to the mRNA, such as 1-methylpseudouridine, to help the body accept the genetic instructions without triggering an unwanted inflammatory reaction. The lipid nanoparticle itself is a precise mixture of an ionizable cationic lipid, a neutral lipid like DSPC, cholesterol, and a PEG-modified lipid.

What it doesn't cover

• —Does not cover vaccines using traditional weakened or inactivated viruses.
• —Does not cover mRNA sequences that encode proteins unrelated to betacoronavirus S proteins.
• —Does not cover delivery methods other than the specific lipid nanoparticle formulations described.
• —Does not cover the use of unmodified (non-chemically modified) mRNA.

The clever bit

The innovation lies in combining a specific, highly optimized lipid nanoparticle formulation with chemically modified mRNA that mimics natural human RNA, allowing the body to produce the viral protein safely without being destroyed by the immune system before it can be recognized.

Why it matters

This patent represents the core technical architecture used by Moderna to rapidly develop its COVID-19 vaccine. By standardizing the delivery vehicle and the mRNA modification process, it enabled a platform approach to vaccine development that can be adapted to different viral targets by simply swapping the genetic code for the specific spike protein.

Real-world examples

• 1.Moderna COVID-19 vaccine (Spikevax)